The impact of ethnicity on response to antihypertensive therapy

The aim of this review is to assess the prevalence of complications and responses to various antihypertensive drug therapies in ethnic minority groups in the United States. In some instances, these comments are extended to responses of citizens in their countries of origin. The incidence of hyperten...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:The American journal of medicine 1996-09, Vol.101 (3), p.22S-32S
Hauptverfasser: Jamerson, Kenneth, DeQuattro, Vincent
Format: Artikel
Sprache:eng
Schlagworte:
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
container_end_page 32S
container_issue 3
container_start_page 22S
container_title The American journal of medicine
container_volume 101
creator Jamerson, Kenneth
DeQuattro, Vincent
description The aim of this review is to assess the prevalence of complications and responses to various antihypertensive drug therapies in ethnic minority groups in the United States. In some instances, these comments are extended to responses of citizens in their countries of origin. The incidence of hypertension, mortality from hypertensive heart disease, stroke, and hypertensive renal disease are higher in African Americans. Although some Hispanic Americans have a lesser risk for hypertension, they have a greater risk for other risk factors such as diabetes and dyslipidemia. There is a similar association between income and mortality for both African Americans and Hispanic Americans. When compared to European Americans and other ethnic minorities, African Americans respond less favorably to β blockers and angiotensin-converting enzyme (ACE) inhibitors. Nevertheless, the observed response in African Americans to ACE inhibitors and β blockers is clinically significant. The available literature indicates that Asian American responses to calcium antagonists seem to be more favorable than responses to ACE inhibitors and equivalent to their responses to diuretic and β blocker therapy. Although there are few published studies of drug efficacy in Hispanic Americans, there appears to be no hierarchy in response to the various antihypertensive drug classes. Ethnicity is not an accurate criterion for predicting poor response to any class of antihypertensive therapy. Thus, there is little justification to use racial profiling as a criterion for the avoidance of selected drug classes because of presumed lack of efficacy. Observed differences in the incidence of hypertension and its poor outcomes have led some investigators to postulate that the etiology of hypertension in ethnic minority groups is intrinsically different from whites. Awareness of racial differences in hypertension outcomes evolved in the United States within a historical context that does not fully appreciate that race is often a surrogate for many social and economic factors that influence health status and healthcare delivery. Poor outcomes in ethnic minority groups occur in many diseases, not only hypertension. The goal of ethnicity-related research should be to describe the diversity of disease expression in humans and to target at-risk groups for prevention and early intervention. The use of racial descriptors to explain genetic differences in ethnic groups should take a lesser priority.
doi_str_mv 10.1016/S0002-9343(96)00265-3
format Article
fullrecord <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_78449852</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><els_id>S0002934396002653</els_id><sourcerecordid>78449852</sourcerecordid><originalsourceid>FETCH-LOGICAL-c302t-f44fb0382b865013102d79177778ced47462bbe31b0c098343b475514da11ef53</originalsourceid><addsrcrecordid>eNqFkE1LAzEQhoMoWqs_obB4ED2s5jvZk0jxCwQP6jnsZmdpSrtZk7TQf29qiwcv5jKZzDtvZh6EJgTfEEzk7TvGmJYV4-yqktf5LkXJDtCICCFKRSQ9RKNfyQk6jXGeU1wJeYyOtVaSKzpCdx8zKNxyqG0qfFdAmvXOurQpfF8EiIPvIxTJF3Wf3GwzQEjQR7fObzMI9bA5Q0ddvYhwvo9j9Pn48DF9Ll_fnl6m96-lZZimsuO8azDTtNFSYMIIpq2qiMpHW2i54pI2DTDSYIsrnSduuBKC8LYmBDrBxuhy5zsE_7WCmMzSRQuLRd2DX0WjNOeVFjQLL_4I534V-jyboYwyQbTauomdyAYfY4DODMEt67AxBJstXfND12zRmUqaH7qG5b7J3nzVLKH97drjzPW7XR0yirWDYKJ10OcNXQCbTOvdPz98AzKKh4E</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>232351875</pqid></control><display><type>article</type><title>The impact of ethnicity on response to antihypertensive therapy</title><source>MEDLINE</source><source>Elsevier ScienceDirect Journals</source><creator>Jamerson, Kenneth ; DeQuattro, Vincent</creator><creatorcontrib>Jamerson, Kenneth ; DeQuattro, Vincent</creatorcontrib><description>The aim of this review is to assess the prevalence of complications and responses to various antihypertensive drug therapies in ethnic minority groups in the United States. In some instances, these comments are extended to responses of citizens in their countries of origin. The incidence of hypertension, mortality from hypertensive heart disease, stroke, and hypertensive renal disease are higher in African Americans. Although some Hispanic Americans have a lesser risk for hypertension, they have a greater risk for other risk factors such as diabetes and dyslipidemia. There is a similar association between income and mortality for both African Americans and Hispanic Americans. When compared to European Americans and other ethnic minorities, African Americans respond less favorably to β blockers and angiotensin-converting enzyme (ACE) inhibitors. Nevertheless, the observed response in African Americans to ACE inhibitors and β blockers is clinically significant. The available literature indicates that Asian American responses to calcium antagonists seem to be more favorable than responses to ACE inhibitors and equivalent to their responses to diuretic and β blocker therapy. Although there are few published studies of drug efficacy in Hispanic Americans, there appears to be no hierarchy in response to the various antihypertensive drug classes. Ethnicity is not an accurate criterion for predicting poor response to any class of antihypertensive therapy. Thus, there is little justification to use racial profiling as a criterion for the avoidance of selected drug classes because of presumed lack of efficacy. Observed differences in the incidence of hypertension and its poor outcomes have led some investigators to postulate that the etiology of hypertension in ethnic minority groups is intrinsically different from whites. Awareness of racial differences in hypertension outcomes evolved in the United States within a historical context that does not fully appreciate that race is often a surrogate for many social and economic factors that influence health status and healthcare delivery. Poor outcomes in ethnic minority groups occur in many diseases, not only hypertension. The goal of ethnicity-related research should be to describe the diversity of disease expression in humans and to target at-risk groups for prevention and early intervention. The use of racial descriptors to explain genetic differences in ethnic groups should take a lesser priority.</description><identifier>ISSN: 0002-9343</identifier><identifier>EISSN: 1555-7162</identifier><identifier>DOI: 10.1016/S0002-9343(96)00265-3</identifier><identifier>PMID: 8876472</identifier><identifier>CODEN: AJMEAZ</identifier><language>eng</language><publisher>United States: Elsevier Inc</publisher><subject>Antihypertensive Agents - therapeutic use ; Asian ; Black or African American ; Black People ; Drug therapy ; Ethnicity ; Health Services Accessibility ; Hispanic or Latino ; Humans ; Hypertension ; Hypertension - drug therapy ; Hypertension - ethnology ; Indians, North American ; Minority &amp; ethnic groups ; United States</subject><ispartof>The American journal of medicine, 1996-09, Vol.101 (3), p.22S-32S</ispartof><rights>1996 Excerpta Medica, Inc. All rights reserved.</rights><rights>Copyright Elsevier Sequoia S.A. Sep 30, 1996</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c302t-f44fb0382b865013102d79177778ced47462bbe31b0c098343b475514da11ef53</citedby><cites>FETCH-LOGICAL-c302t-f44fb0382b865013102d79177778ced47462bbe31b0c098343b475514da11ef53</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktohtml>$$Uhttps://dx.doi.org/10.1016/S0002-9343(96)00265-3$$EHTML$$P50$$Gelsevier$$H</linktohtml><link.rule.ids>314,777,781,3537,27905,27906,45976</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/8876472$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Jamerson, Kenneth</creatorcontrib><creatorcontrib>DeQuattro, Vincent</creatorcontrib><title>The impact of ethnicity on response to antihypertensive therapy</title><title>The American journal of medicine</title><addtitle>Am J Med</addtitle><description>The aim of this review is to assess the prevalence of complications and responses to various antihypertensive drug therapies in ethnic minority groups in the United States. In some instances, these comments are extended to responses of citizens in their countries of origin. The incidence of hypertension, mortality from hypertensive heart disease, stroke, and hypertensive renal disease are higher in African Americans. Although some Hispanic Americans have a lesser risk for hypertension, they have a greater risk for other risk factors such as diabetes and dyslipidemia. There is a similar association between income and mortality for both African Americans and Hispanic Americans. When compared to European Americans and other ethnic minorities, African Americans respond less favorably to β blockers and angiotensin-converting enzyme (ACE) inhibitors. Nevertheless, the observed response in African Americans to ACE inhibitors and β blockers is clinically significant. The available literature indicates that Asian American responses to calcium antagonists seem to be more favorable than responses to ACE inhibitors and equivalent to their responses to diuretic and β blocker therapy. Although there are few published studies of drug efficacy in Hispanic Americans, there appears to be no hierarchy in response to the various antihypertensive drug classes. Ethnicity is not an accurate criterion for predicting poor response to any class of antihypertensive therapy. Thus, there is little justification to use racial profiling as a criterion for the avoidance of selected drug classes because of presumed lack of efficacy. Observed differences in the incidence of hypertension and its poor outcomes have led some investigators to postulate that the etiology of hypertension in ethnic minority groups is intrinsically different from whites. Awareness of racial differences in hypertension outcomes evolved in the United States within a historical context that does not fully appreciate that race is often a surrogate for many social and economic factors that influence health status and healthcare delivery. Poor outcomes in ethnic minority groups occur in many diseases, not only hypertension. The goal of ethnicity-related research should be to describe the diversity of disease expression in humans and to target at-risk groups for prevention and early intervention. The use of racial descriptors to explain genetic differences in ethnic groups should take a lesser priority.</description><subject>Antihypertensive Agents - therapeutic use</subject><subject>Asian</subject><subject>Black or African American</subject><subject>Black People</subject><subject>Drug therapy</subject><subject>Ethnicity</subject><subject>Health Services Accessibility</subject><subject>Hispanic or Latino</subject><subject>Humans</subject><subject>Hypertension</subject><subject>Hypertension - drug therapy</subject><subject>Hypertension - ethnology</subject><subject>Indians, North American</subject><subject>Minority &amp; ethnic groups</subject><subject>United States</subject><issn>0002-9343</issn><issn>1555-7162</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>1996</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNqFkE1LAzEQhoMoWqs_obB4ED2s5jvZk0jxCwQP6jnsZmdpSrtZk7TQf29qiwcv5jKZzDtvZh6EJgTfEEzk7TvGmJYV4-yqktf5LkXJDtCICCFKRSQ9RKNfyQk6jXGeU1wJeYyOtVaSKzpCdx8zKNxyqG0qfFdAmvXOurQpfF8EiIPvIxTJF3Wf3GwzQEjQR7fObzMI9bA5Q0ddvYhwvo9j9Pn48DF9Ll_fnl6m96-lZZimsuO8azDTtNFSYMIIpq2qiMpHW2i54pI2DTDSYIsrnSduuBKC8LYmBDrBxuhy5zsE_7WCmMzSRQuLRd2DX0WjNOeVFjQLL_4I534V-jyboYwyQbTauomdyAYfY4DODMEt67AxBJstXfND12zRmUqaH7qG5b7J3nzVLKH97drjzPW7XR0yirWDYKJ10OcNXQCbTOvdPz98AzKKh4E</recordid><startdate>19960930</startdate><enddate>19960930</enddate><creator>Jamerson, Kenneth</creator><creator>DeQuattro, Vincent</creator><general>Elsevier Inc</general><general>Elsevier Sequoia S.A</general><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7T5</scope><scope>7TK</scope><scope>7TO</scope><scope>7TS</scope><scope>7U9</scope><scope>H94</scope><scope>K9.</scope><scope>7X8</scope></search><sort><creationdate>19960930</creationdate><title>The impact of ethnicity on response to antihypertensive therapy</title><author>Jamerson, Kenneth ; DeQuattro, Vincent</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c302t-f44fb0382b865013102d79177778ced47462bbe31b0c098343b475514da11ef53</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>1996</creationdate><topic>Antihypertensive Agents - therapeutic use</topic><topic>Asian</topic><topic>Black or African American</topic><topic>Black People</topic><topic>Drug therapy</topic><topic>Ethnicity</topic><topic>Health Services Accessibility</topic><topic>Hispanic or Latino</topic><topic>Humans</topic><topic>Hypertension</topic><topic>Hypertension - drug therapy</topic><topic>Hypertension - ethnology</topic><topic>Indians, North American</topic><topic>Minority &amp; ethnic groups</topic><topic>United States</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Jamerson, Kenneth</creatorcontrib><creatorcontrib>DeQuattro, Vincent</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>Immunology Abstracts</collection><collection>Neurosciences Abstracts</collection><collection>Oncogenes and Growth Factors Abstracts</collection><collection>Physical Education Index</collection><collection>Virology and AIDS Abstracts</collection><collection>AIDS and Cancer Research Abstracts</collection><collection>ProQuest Health &amp; Medical Complete (Alumni)</collection><collection>MEDLINE - Academic</collection><jtitle>The American journal of medicine</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Jamerson, Kenneth</au><au>DeQuattro, Vincent</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>The impact of ethnicity on response to antihypertensive therapy</atitle><jtitle>The American journal of medicine</jtitle><addtitle>Am J Med</addtitle><date>1996-09-30</date><risdate>1996</risdate><volume>101</volume><issue>3</issue><spage>22S</spage><epage>32S</epage><pages>22S-32S</pages><issn>0002-9343</issn><eissn>1555-7162</eissn><coden>AJMEAZ</coden><abstract>The aim of this review is to assess the prevalence of complications and responses to various antihypertensive drug therapies in ethnic minority groups in the United States. In some instances, these comments are extended to responses of citizens in their countries of origin. The incidence of hypertension, mortality from hypertensive heart disease, stroke, and hypertensive renal disease are higher in African Americans. Although some Hispanic Americans have a lesser risk for hypertension, they have a greater risk for other risk factors such as diabetes and dyslipidemia. There is a similar association between income and mortality for both African Americans and Hispanic Americans. When compared to European Americans and other ethnic minorities, African Americans respond less favorably to β blockers and angiotensin-converting enzyme (ACE) inhibitors. Nevertheless, the observed response in African Americans to ACE inhibitors and β blockers is clinically significant. The available literature indicates that Asian American responses to calcium antagonists seem to be more favorable than responses to ACE inhibitors and equivalent to their responses to diuretic and β blocker therapy. Although there are few published studies of drug efficacy in Hispanic Americans, there appears to be no hierarchy in response to the various antihypertensive drug classes. Ethnicity is not an accurate criterion for predicting poor response to any class of antihypertensive therapy. Thus, there is little justification to use racial profiling as a criterion for the avoidance of selected drug classes because of presumed lack of efficacy. Observed differences in the incidence of hypertension and its poor outcomes have led some investigators to postulate that the etiology of hypertension in ethnic minority groups is intrinsically different from whites. Awareness of racial differences in hypertension outcomes evolved in the United States within a historical context that does not fully appreciate that race is often a surrogate for many social and economic factors that influence health status and healthcare delivery. Poor outcomes in ethnic minority groups occur in many diseases, not only hypertension. The goal of ethnicity-related research should be to describe the diversity of disease expression in humans and to target at-risk groups for prevention and early intervention. The use of racial descriptors to explain genetic differences in ethnic groups should take a lesser priority.</abstract><cop>United States</cop><pub>Elsevier Inc</pub><pmid>8876472</pmid><doi>10.1016/S0002-9343(96)00265-3</doi></addata></record>
fulltext fulltext
identifier ISSN: 0002-9343
ispartof The American journal of medicine, 1996-09, Vol.101 (3), p.22S-32S
issn 0002-9343
1555-7162
language eng
recordid cdi_proquest_miscellaneous_78449852
source MEDLINE; Elsevier ScienceDirect Journals
subjects Antihypertensive Agents - therapeutic use
Asian
Black or African American
Black People
Drug therapy
Ethnicity
Health Services Accessibility
Hispanic or Latino
Humans
Hypertension
Hypertension - drug therapy
Hypertension - ethnology
Indians, North American
Minority & ethnic groups
United States
title The impact of ethnicity on response to antihypertensive therapy
url https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-20T02%3A07%3A38IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=The%20impact%20of%20ethnicity%20on%20response%20to%20antihypertensive%20therapy&rft.jtitle=The%20American%20journal%20of%20medicine&rft.au=Jamerson,%20Kenneth&rft.date=1996-09-30&rft.volume=101&rft.issue=3&rft.spage=22S&rft.epage=32S&rft.pages=22S-32S&rft.issn=0002-9343&rft.eissn=1555-7162&rft.coden=AJMEAZ&rft_id=info:doi/10.1016/S0002-9343(96)00265-3&rft_dat=%3Cproquest_cross%3E78449852%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=232351875&rft_id=info:pmid/8876472&rft_els_id=S0002934396002653&rfr_iscdi=true